A trader's look at Neuralstem

Shares of Neuralstem (CUR +9.7%) rebound off the key technical support level of the 200-day MA albeit on less-than-average volume. The $3 price point also represents a support level that was established in late January/early February.

The relative strength line has turned up and the RS rating remains robust at 96 (99=best possible).

Swing traders should consider keeping their powder dry until a high volume confirmation move takes place or it ends the week above the 10-wk EMA on higher volume. Otherwise, there is a risk the 10-wk EMA is a resistance level and prices retreat.

The long-term uptrend that began in April 2013 remains intact.

Comments (7)
  • Davephd
    , contributor
    Comments (1212) | Send Message
    I wouldn't think this would be a traders stock. Depending on how their research and trials go they are either a 10 bager, a bust, or a buy out candidate. Their research and trial results are looking better and better.
    14 May 2014, 04:00 PM Reply Like
  • Pman701
    , contributor
    Comments (206) | Send Message
    Agree however still am concerned about the lawsuit and what the outcome will be.
    14 May 2014, 04:14 PM Reply Like
  • Davephd
    , contributor
    Comments (1212) | Send Message
    I am not worried about the STEM patent situation. It is amazing how many patents are ruled invalid when tested in court litigation.


    Here is a quote from the YAHOO CUR message board, for what it is worth: "No Stem doesn't own any of the patents that CUR holds! CUR's CEO and cofounder of Neuralstem is a Lawyer who specializes in corporate and patent law. CUR is holding it's own patents for it's products/technology and Stem has been trying to sue CUR for over 10 years without any success!"
    14 May 2014, 05:34 PM Reply Like
  • Len Friedman
    , contributor
    Comments (93) | Send Message
    Agree as well here but with a caveat: I added 500 this week at $3.04 thinking a swing trade. But seeing it moving back up with a stable bottom and a delicious upward bias today despite strong market sentiment going in reverse has me rethinking and not likely to sell. Now holding 3,000 @ a c.b. of $!.56 and happy. I'm thinking this could approach $4 again fairly soon.


    It might be wise to keep in mind that ALS isn't the only application being scrutinized here. Stroke and spinal cord injuries also need be factored in. I'm not worried that one portal might close for there are two others. And even if one should be shut down, isn't it possible if not likely that things learned through ongoing efforts will contribute to another situation---such as Alzheimer's disease?


    This is not an all-or-nothing scenario by a longshot. And I'm hopeful our community here will help push public sentiment along to help others.


    My opinions only in the above.
    14 May 2014, 05:39 PM Reply Like
  • Prooker
    , contributor
    Comments (8) | Send Message
    Did i read somewhere recently that CUR had $30 million case on hand?
    14 May 2014, 06:38 PM Reply Like
  • smithson
    , contributor
    Comments (3) | Send Message
    CUR has the correct research to build a tremendous future. It will most likely be a buyout target by the end of 2014.
    14 May 2014, 10:40 PM Reply Like
  • toosmarttofail
    , contributor
    Comments (706) | Send Message
    Non-embryonic stemcell company runs up on hype...ATHX anyone?


    ACTC is best-of-breed. Their Dr. Lanza even published a paper about how adult cells are 30,000x weaker than embryonic, and for good measure he did another paper on how to properly create an ipsc.


    This stock has a lot of ground to erode from its hype-driven highs. Phase II is where non-embryonic stem companies go to die.
    15 May 2014, 06:36 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs